Baricitinib 'potential therapeutic option' for moderate to severe atopic dermatitis
A 4 mg dose of baricitinib was associated with significant improvement over placebo in a number of efficacy parameters in patients with moderate to severe atopic dermatitis, according to a study. “Baricitinib, an oral selective Janus kinase (JAK)1/JAK2 inhibitor, is approved in many countries for moderate-to-severe atopic dermatitis (AD) in adult patients who are candidates
Source: healio.com